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[57] ABSTRACT 
A method for the qualitative assessment of oxidative 
drug metabolism de?ciencies, preferably for the qualita 
tive assessment of dextromethorphan metabolism, in a 
subject comprises analyzing a sample ?uid from the 
subject, for example urine, which contains metabolites 
of a probe drug using high performance thin layer chro 
matography. 
8 Claims, No Drawinm 
1 
QUALITATIVE METABOLISM ASSESSMENT 
USING HIGH PERFORMANCE THIN LAYER 
CHROMATOGRAPHY 
FIELD OF THE INVENTION 
The present invention relates to a method for the 
qualitative assessment of oxidative drug metabolism 
de?ciencies in a subject. The subject may be human or 
a nonhuman animal. The present invention further re 
lates to a method for the qualitative assessment of dex 
tromethorphan metabolism in a subject. 
BACKGROUND OF THE INVENTION 
Interest in the pharmacogenetics of oxidative drug 
metabolism has grown rapidly in the past several years. 
It has been discovered that a genetic de?ciency in oxi 
dative drug metabolism exists in certain subjects which 
causes the subjects to act as a slow or poor metabolizer 
rather than a fast, ef?cient or extensive metabolizer of 
certain drugs. Several drugs have been used as probes 
for the assessment of oxidative drug metabolism de? 
ciencies in subjects, including dextromethorphan, de 
brisoquine and sparteine. See, for example, Kupfer et al, 
“Dextromethorphan as a Safe Probe for Debrisoquine 
Hydroxylation Polymorphism”, The Lancet (Sept. 1, 
1984), pages 517-518; Roy et al, “Methoxyphenamine 
and Dextromethorphan as Safe Probes for Debriso 
quine Hydroxylation Polyamorphism”, The Lancet 
(Dec. 15, 1984), page 1393; Schmid et a1, “Polymorphic 
Dextromethorphan Metabolism: (Jo-Segregation of 
Oxidative O-Demethylation with Debrisoquine Hy 
droxylation”, Clinical Pharmacology and Therapeutics, 
Vol. 38, No. 6 (1985), pages 618-624; De Zeeuw et al, 
“Interindividual Differences in Dextromethorphan Ki 
netics in Man”, Acta Pharmacologica et Toxicologica, 
Vol. 59, Supplement V (1986), page 44; and Kupfer et 
al, “Pharmacogenetics of Dextromethorphan O-Demet 
hylation in Man”, Xenobiotica, Vol. 16, No. 5 (1986), 
pages 421-433, for ?irther details of previous studies in 
this regard. ' " 
Generally, pharmacogenetic screening using the 
aforementioned or other drugs as probes has been con 
ducted by administering the probe drug to a subject and 
then quantitatively monitoring a. body ?uid containing 
metabolites of the probe drug. Known methods for 
analyzing body ?uids such as urine containing the drug 
and its metabolites include gas chromatography and 
high performance liquid chromatography. Both gas 
chromatography and high performance liquid chroma 
tography provide a quantitative indication of the rela 
tive amounts of the probe drug and the metabolites of 
the probe drug in the sampled body ?uid. The gas chro 
matography and high performance liquid chromatogra 
phy method are‘ particularly suitable for determining 
the relative amounts of the substances. Reports of phar 
macogenetic screenings using either gas chromatogra 
phy or high performance liquid chromatography tech 
niques are disclosed by, for example, Price Evans et al, 
Journal of Medical Genetics, 17 (1980), pages 102-105 
(gas chromatography); Kupfer et al, European Journal 
of Clinical Pharmacology, 26 (1984,) pages 753-759 (gas 
liquid chromatograph); Wedlund etal, Clinical Pharma 
cology and Therapeutics, Vol. 36, No. 6 (1984), pages 
773-780 (high performance liquid chromatography); 
Jurima et al, British Journal of Clinical Pharmacology, 19 
(1985), pages 483-487 (gas chromatography); and Bi 
4,877,744 
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2 
chelbaum et al, Xenobiotica, Vol. 16, No. 5 (1986), pages 
465-481 (gas chromatography). 
Additionally, determinations of dextromethorphan 
and its metabolites using high pressure liquid chroma 
tography suitable for use in pharmacogenetic screening 
procedures are disclosed by Park et al, Journal of Phar 
maceulical Sciences, Vol. 73, No. 1 (1984), pages 24-29; 
Achari et al, Journal of Pharmaceutical Sciences, -Vol. 73, 
No. 12 (1984), pages 1821-1822; and East et al, Journal 
of Chromatography, 338 (1985), pages 99-112. 
While gas chromatography and high performance 
liquid chromatography are advantageous in providing 
quantitative analyses of oxidative drug metabolism dur 
ing pharmacogenetic screening, these methods are dis 
advantageous in that they require complex, expensive 
equipment, including chromatographic columns, and in 
that they are time consuming. For example, in a typical 
arrangement, a high pressure liquid chromatography 
apparatus permits only one analysis per ten minute per 
iod. Thus, a need exists for a faster method of analysis in 
pgenetic screening of oxidative drug metabo 
lisms. A. need also exists for such a method of analysis 
which uses more simple and inexpensive equipment 
than that required in the gas and high performance 
liquid chromatography techniques. 
SUMMARY OF THE INVENTION 
It is therefore an object of the present invention to 
provide a method for the assessment of oxidative drug 
metabolisms which is both more time ef?cient and inex 
pensive as compared with prior known methods. It is a 
more speci?c object of the present invention to provide 
a method for the ment of oxidative drug metabo 
lism de?ciencies which is both time ef?cient and inex 
pensive. 
It is a further object of the present invention to pro 
vide a method for the qualitative assessment of oxida 
tive drug metabolism, particularly oxidative drug me 
tabolism de?ciencies, for use in time ef?cient and inex 
pensive pharmacogenetic screening procedures and 
phenotyping procedures. It is a further object of the 
present invention to provide a method for the qualita 
tive assessment of dextromethorphan metabolism which 
may be performed both rapidly and economically. 
These and additional objects are provided according 
to the present invention which generally comprises a 
method for the qualitative assessment of oxidative drug 
metabolism de?ciencies in a subject. The method com 
prises analyzing a sample ?uid from the subject, for 
example urine, which contains metabolites of a probe 
drug using high performance thin layer chromatogra 
phy. A probe drug may be de?ned as a drug which is 
administered to a subject in a controlled amount in 
order to investigate metabolic characteristics of the 
subject with respect to the probe drug. High perfor 
mance thin layer chromatography is classi?ed under the 
general category of adsorption and/or partition chro» 
matography and is generally known in the art. See, for 
example, Practice of Thin Layer Chromatography, Sec» 
0nd Edition, J. C. Touchstone and M. F. Dobbins, John 
Wiley & Sons, Inc. New York, 1983, which is incorpo-: 
rated herein by reference. It has been discovered that by 
combining high performance thin layer chromatogra 
phy with the use of probe drugs in determining oxida 
tive drug metabolism de?ciencies, a method is provided 
for the rapid, ef?cient and inexpensive qualitative as 
sessment of oxidative drug metabolism de?ciencies. 
4,877,744 
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These and additional objects and advantages pro 
vided by the method of the present invention will be 
come more fully understood in view of the following 
detailed description. 
DETAILED DESCRIPTION 
The present invention generally relates to a method 
for the qualitative assessment of oxidative drug metabo 
lism de?ciencies. The method allows for rapid, efficient 
and inexpensive phenotyping and pharmacogenetic 
screening of subjects. The method comprises analyzing 
a sample ?uid from the subject which contains metabo~= 
lites of a probe drug using high performance thin layer 
chromatography. The subject may be human or a non= 
human animal and suitably the sample ?uid which is 
analyzed comprises urine. ‘ 
As is known in the art, high performance thin layer 
chromatography is a speci?c type of adsorption and/ or } 
partition chromatography wherein the moving phase is 
liquid and the stationary phase is a solid adsorbing or 
partitioning material deposited on a ?at supporting 
surface. The general procedures for high performance 
liquid chromatography are more fully described in 
Practice of Thin Layer Chromatography, Second Edition, 
cited above and incorporated herein by reference. Gen~= 
erally, the ?at supporting surface comprises a glass plate 
although the ?at plate may also be formed of materials 
such as ceramic or synthetic plastic materials including 
thermosetting and thermoplastic polymers. The adsor~= 
bent and/or partitioning material may comprise any of 
the conventional materials known in the art such as 
silica gel, alumina, diatomaceous earth, cellulose, re 
verse phase substances or mixtures thereof. Optionally, 
a binding agent, for example starch or the like, may be 
mixed with the adsorbent material to hold it in place on 
the ?at plate. The adsorbent material is formed in a thin 
layer, for example having a thickness of 0.1 to 2.0 milli 
meters, on the ?at plate. 
Asample which is to be analyzed using high perfor 
mance thin layer chromatography is generally mixed 
with a solvent and applied as a spot to the adsorbent 
surface of the plate. Thus, in accordance with the pres 
ent invention, a sample ?uid from the subject which 
contains metabolites of the probe drug, preferably 
urine, is mixed with a solvent and applied as a spot to 
the thin layer adsorbent surface deposited on the plate. 
With the assistance of the high performance tech 
nique and capillary action, a solvent such as Davidow 
(composed of ethyl acetate 85 parts, methanol 10 parts 
and ammonium hydroxide 5 parts) or any other appro 
priate solvent systems known to the art for use in thin 
layer chromatography migrates up the thin layer of 
adsorbent material. Simultaneously, the various constit= 
nents of the sample ?uid migrate along the adsorbent 
material to resolve the original spot of mixture into a 
series of spots corresponding to each or several compo 
nents of the mixture. For example, any remainder of the 
probe drug and any of its di?'erent metabolites con 
tained in the sample migrate along the adsorbent mate= 
rial to resolve the original spot of sample ?uid into a 
series of spots corresponding to each probe component 
or several components, thereby separating the drug 
from its metabolites. The spots may be visualized by 
spraying them with a suitable color producing agents 
such as the known Dragendorff’s reagent followed by 
5% sodium nitrite spray or any other established visual 
ization reagents known in the art for use with thin layer 
chromatography. According to the present invention, it 
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has been discovered that the high performance thin 
layer chromatography is particularly suitable for re 
solving a sample of body ?uid containing a probe drug 
and its various metabolites into a series of spots corre 
sponding to each component thereby forming a chro 
matogram. 
In a preferred method according to the present inven 
tion, the subject under study is a dosage of 
a probe drug. Thereafter, a body ?uid of the subject 
which contains the metabolites of the probe drug, for 
example urine, is continuously collected, and the col-: 
lected ?uid is analyzed using high performance thin 
layer chromatography as discussed above. The high 
performance thin layer chromatography is particularly 
adapted for resolving the sample body ?uid and separat 
ing the various metabolites contained therein from one 
another and from any unmetabolized probe drug. More 
over, once the resolved spots are visualized, visual ob 
servation of the thin layer plate will indicate a qualita 
tive assessment of the subject’s probe drug metabolism 
characteristics. Particularly, the chromatography will 
visually indicate whether there is a signi?cantly greater 
amount of unmetabolized drug contained in the sample 
whereby the subject is a slow or poor oxidative drug 
metabolizer, or whether there is a relatively greater 
amount of the different metabolites contained in the 
sample whereby the subject is a fast or ef?cient oxida 
tive drug metabolizer. 
A more speci?c embodiment of the present invention 
comprises a method for the qualitative assessment of 
dextromethorphan metabolism in a subject. The method 
comprises analyzing a sample ?uid from the subject 
which contains dextromethorphan metabolites using 
high performance thin layer chromatography as dis 
cussed above. Preferably, the subject is administerd a 
dosage of dextromethorphan, a body ?uid of the subject 
which contains dextromethorphan metabolites, prefera 
bly urine, is continuously collected, and the collected 
body ?uid is analyzed using high performance thin 
layer chromatography. 
According to the method of the present invention, 
qualitative screening of patients for a de?ciency in oxi 
dative drug metabolism, for example the de?ciency 
affecting dextromethorphan metabolism, may be per= 
formed rapidly and economically. Thus, such screen» 
ings can be performed prior to initiating therapy with 
drugs in?uenced by the oxidative drug metabolism 
de?ciencies. The following example demonstrates the 
suitability of the method of the present invention for 
qualitative screening of patients. 
EXAMPLE 
This example demonstrates the method of the present 
invention using human subjects. A control urine sample 
was taken from each of twelve subjects prior to begin 
ning the testing procedure. Each subject then ingested 
60mg of dextromethorphan, and complete urine collec 
tion was performed for 8 hours after drug administra 
tion. Each urine same, including the control samples, 
was analyzed using high performance thin layer chro= 
matography. Speci?cally, following urine hydrolysis 
and extraction, samples were dissolved in dichloro 
methane and spotted on a 10 cm high performance thin 
layer chromatography silica gel plate. The plate was 
placed in a sealed glass tank containing the mobile phase 
solvent (composed of ethylacetate 85 parts: methanol 10 
pinata-‘normal hydroxide 5 parts) and developed 
vertically for 5 cm. The plate was removed from the 
4,877,744 
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tank, dried and then sprayed with Lady Tenger reagent 
(containing 5 gm bismuth subcarbonate +15 ml hydro 
chloric acid +15 gm of potassium iodide and 85 ml of 
water) followed by a 5% sodium nitrite spray. For 
comparison, all samples were also analyzed using high 
performance liquid chromatography methods. Qualita 
tive examination of the chromatograms resulting from 
the high pressure thin layer chromatography clearly 
distinguished l0 ef?cient or fast metabolizer phenotypes 
and 2 slow or poor metabolizer phenotypes in the 
group. No interfering substances were detected in any 
of the control urine samples. For con?rmation, accord 
ing to the high performance liquid chromatography 
method, dextromethorphan and two of its metabolites, 
dextrorphan and (+)-3=morphinanol were quanti?ed in 
each urine sample using ?uorescence detection. The 
ratios between dextromethorphan and the dextrorphan 
metabolite ranged between 0.02 and 0.05 for 10 of the 
subjects, i.e., the fast or e?icient metabolizers indicated 
in the high pressure thin layer chromatography results. 
The ratio of dextromethorphan and the dextrorphan 
metabolite for the remaining 2 subjects were 7.5 and 
16.2, thus con?rming the qualitative indication of the 2 
slow or poor metabolizer noted from the high perfor 
mance thin layer chromatography results. As with the 
high pressure thin layer chromatography method, no 
interfacing substances were detected in any of the con 
trol urines by the high performance liquid chromatogra 
phy method. Thus, the method according to the present 
invention provides a rapid, efficient and economical 
means for qualitatively screening patients for de?cien 
cies in oxidative drug metabolism, particularly dextro~ 
methorphan metabolism. 
The preceding Example is set forth to illustrate a 
speci?c embodiment of the invention and is not in= 
tended to limit the scope of the methods of the present 
invention. Additional embodiments and advantages 
within the scope of the claimed invention will be appar 
ent to one of ordinary skill in the art. 
What is claimed is: 
1. In a method for characterizing the oxidative phe 
notype of a subject comprising collecting a fluid sample 
from the subject, analyzing the sample to quantitatively 
determine the presence of oxidative metabolites of a 
drug and comparing the results obtained for the subject 
with those obtained for a normal subject subsequent to 
the administration of said drug, the improvement 
wherein 
the analyzing step is rapidly conducted by high per 
formance thin layer chromatography to qualita 
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tively assess the metabolite pattern of the subject; 
and 
the comparing step is conducted by visually compar 
ing the subject's metabolite pattern to a normal 
subject's metabolite pattern. 
2. The method of claim 1, wherein 
the drug is dextramethorfan; and 
the sample is urine. 
3. The method of claim 1, wherein 
the thin layer chromatography is performed on an 
adsorbent layer of a material selected from the 
group consisting of silica gel, alumina, diatoma 
ceous earth, cellulose, and mixtures thereof on a 
?at plate formed of a material selected from the 
group consisting of glass, ceramic, and synthetic 
plastic materials. 
4. The method of claim 1, wherein the collecting, 
analyzing and comparing steps are repeated at a speci 
?ed time interval. 
5. In a method for characterizing the oxidative phe= 
notype of a subject comprising administering to the 
subject an amount of a probe drug effective to yield 
detectable amounts of the drug and its oxidative metab 
olites in a ?uid sample of the subject taken at a speci?ed 
time subsequent to the administration of the drug, col 
lecting a ?uid sample from the subject, analyzing the 
?uid sample to quantitatively determine the exact ratio 
of drug to metabolites present in the sample and com 
paring the subject’s ratio to a normal oxidative ratio, the 
improvement wherein 
the analyzing step is rapidly conducted by high per 
formance thin layer chromatography to qualita 
tively assess the metabolite, pattern of the subject; 
and 
the comparing step is conducted by visually compar 
ing the subject’s pattern to a normal subject's me 
tabolite pattern. 
6. The method of claim 5, wherein 
the drug is dextramethorfan; and 
the sample is urine. 
7. The method of claim 5, wherein 
the thin layer chromatography is performed on an 
adsorbent layer of a material selected from the 
group consisting of silica gel, alumina, diatoma 
ceous earth, cellulose, and mixtures thereof on a 
?at plate formed of a material ‘selected from the 
group consisting of glass, ceramic, and synthetic 
plastic materials. 
8. The method of claim 5, wherein 
the collecting, analyzing and comparing steps are 
repeated at a speci?ed'time interval. 
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